Sign in
RNLX Stock Price, Chart, Stats & News
Renalytix Plc
Save
22.55M
Market cap
–
Current P/E
–
Forward P/E
RNLX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 6.82% |
Operating margin | -1293.49% |
Pretax margin | -1461.42% |
Net margin | -1461.60% |
Effective tax rate | -0.01% |
ROA | -419.67% |
ROE | -631.25% |
D/E | -1.09x |
Interest coverage ratio | – |
RNLX valuation
P/E | – |
P/S | 9.85x |
P/B | -1.43x |
P/CF | -0.37x |
P/FCF | -0.75x |
P/OCF | -0.37x |
PEG | -0.02x |
EV multiple | -0.66x |
About
Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc until its name change in June 2021, focuses on creating artificial intelligence-driven in vitro diagnostic tools for kidney ailments. Its primary product, KidneyIntelX, is an advanced diagnostic system that utilizes an AI-powered algorithm. This algorithm integrates multiple data sources, including scientifically validated blood markers, genetic predispositions, and individual patient information from electronic health records, to produce a distinct risk score for kidney disease.
Similar securities
Based on sector and market capitalization
Report issue